May 2026: Global license-out of bispecific antibody MT-103 to Memento Medicines
Jan 2026: Completed absorption merger with API company Daesung Pharmtech; API sales revenue generated (1,049 million KRW)
Cash and cash equivalents 5,050 million KRW, short-term financial products 15,000 million KRW, total 20,050 million KRW (borrowings 11,000 million + convertible bonds 771 million)
Quarterly net loss 3,144 million KRW (continued loss)
Rivasterat (CU06) proceeding independently after license termination; IND submission for phase 2b expected in 2026
Designation as unfaithful disclosure corporation with penalty (20 million KRW fine)